From synthetic biology to biopharmaceuticals, end-to-end equipment capability is becoming a core competitive edge.

The rapid advancement of synthetic biology is reshaping the foundational logic of the pharmaceutical industry. Through engineered strain development, drug intermediates and active ingredients—traditionally reliant on chemical synthesis characterized by high cost, toxicity, and low yield—are increasingly being replaced by bio-fermentation methods. From recombinant proteins and monoclonal antibodies to vaccine raw materials, more biologics are transitioning from laboratory research to industrial-scale production.

 This trend imposes systematic demands on biopharmaceutical equipment: Can upstream processes support large-scale, high-density fermentation? Can downstream operations achieve efficient separation and purification? These are the core topics Triowin Group aims to discuss with industry peers at PMEC 2026.

Triowin Biopharmaceutical Equipment End-to-End Engineering Delivery Capability from Fermentation to Purification

 Triowin’s bioengineering division focuses on the biopharmaceutical sector, offering EPC/EPCM turnkey solutions that integrate formulation R&D, process design, equipment manufacturing, installation & commissioning, and intelligent control.

At this exhibition, we will highlight our 50–500L two-stage fermentation system, designed to meet evolving needs across all stages of biotechnology and pharmaceutical science. Suitable for microbial fermentation to cell culture, it enables controlled cultivation of microorganisms, human cells, and animal/plant cells. The system supports simultaneous control of 1, 2, 4, or 8 bioreactor units, with working volumes ranging from 50 to 500 liters.

 It flexibly adapts to the full workflow—from shake-flask pilot processes to pilot-scale production. Compliant with GMP design standards, the system ensures aseptic production, process validation, and data traceability throughout. It is ideal for protein/enzyme reactions, microbial fermentation, and cell culture systems, serving applications such as human/animal vaccines, monoclonal antibodies, and gene therapy products. We will also showcase the high-speed pharmaceutical-grade disc stack separator, designed by KMA (Kaimaidi)—a Triowin subsidiary—specifically for the biopharmaceutical industry. It efficiently separates cells, bacteria, and protein precipitates within the 0.5–500μm particle size range, widely used in vaccine, blood product, insulin, and antibody manufacturing.

The equipment supports online CIP/SIP. Product-contact parts use 316L or higher-grade materials (optional 0.4μm electropolish). Seals comply with USP Class VI. The control system employs Siemens S7‑1500 series PLC and comes with complete GMP documentation (FDS/HDS/SDS/DQ/IQ/OQ/RA). 

Combined with Triowin’s expertise in extraction, crystallization, evaporation, and other separation & purification unit operations, we offer integrated process packages—from fermentation broth handling to target product recovery. From fermentation to purification, from standalone equipment to entire lines, Triowin helps biopharma clients build seamless, end-to-end pathways from strain to finished product.

 PMEC 2026

We look forward to welcoming you at Booth N3G12. 

If you are focused on upgrading fermentation equipment, optimizing downstream separation & purification processes, or exploring turnkey solutions, we invite you to visit Triowin Booth N3G12 for discussion.

 Exhibition Information

Event: PMEC China – 19th World Pharmaceutical Machinery, Packaging Equipment & Materials Exhibition

Dates: June 16–18, 2026

Venue: Shanghai New International Expo Centre

Triowin Booth: N3G12